Drug Profile
Research programme: companion diagnostic tests - Abbott/GlaxoSmithKline
Latest Information Update: 01 Mar 2023
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; GlaxoSmithKline Biologicals
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma; Non-small cell lung cancer
Most Recent Events
- 01 Mar 2023 Discontinued - Preclinical for Malignant melanoma (Diagnosis) in USA (unspecified route)
- 01 Mar 2023 Discontinued - Preclinical for Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Malignant-melanoma(Diagnosis) in USA